SEMA4C as a Relapse Biomarker in Breast Cancer
Maneno muhimu
Kikemikali
Maelezo
Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Although regular clinical examination, mammography, ultrasonography, and magnetic resonance imaging can detect some recurrence patients, the lack of robust biomarkers for monitoring of anti-tumor therapies and detection of recurrence reduce the treatment effectiveness of current strategies for breast cancer.
Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. The study is undertaken to explore SEMA4C's potential role as an early relapse biomarker in breast cancer.
Tarehe
| Imethibitishwa Mwisho: | 08/31/2018 |
| Iliyowasilishwa Kwanza: | 09/02/2018 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 09/04/2018 |
| Iliyotumwa Kwanza: | 09/09/2018 |
| Sasisho la Mwisho Liliwasilishwa: | 09/04/2018 |
| Sasisho la Mwisho Lilichapishwa: | 09/09/2018 |
| Tarehe halisi ya kuanza kwa masomo: | 08/31/2019 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 07/31/2021 |
| Tarehe ya Kukamilisha Utafiti: | 07/31/2026 |
Hali au ugonjwa
Uingiliaji / matibabu
Other: SEMA4C high value follow-up group
Other: SEMA4C low value follow-up group
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| SEMA4C high value follow-up group Postoperative SEMA4C value is higher than 5.00 ng/ml. | Other: SEMA4C high value follow-up group Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits. |
| SEMA4C low value follow-up group Postoperative SEMA4C value is lower than 5.00 ng/ml. | Other: SEMA4C low value follow-up group Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | Female |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Have histologically confirmed new diagnosis of breast cancer according to biopsy or surgery Exclusion Criteria: - Patients who are not mentally capable of giving written informed consent - Serum samples doesn't qualified - Patients who refuse follow-up on their conditions - Patients with prior cancer history - Patients with a diagnosis of other severe acute or chronic medical may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study |
Matokeo
Hatua za Matokeo ya Msingi
1. Value of SEMA4C in predicting recurrence of breast cancer [5 years]
Hatua za Matokeo ya Sekondari
1. Disease Free Survival [5 years]
2. Questionnaire about Quality of Life [5 years]
